Table 3.

Primary and secondary outcomes at baseline, 12 weeks, and 26 weeks follow-up

	Baseline		12 weeks				26 weeks
	n	Mean score (SD)	n	Mean score (SD)	Mean adjusted differencea (95% CI); P-value	n	Mean score (SD)	Mean adjusted differencea (95% CI); P-value
Depression (BDI-II score)
Intervention	302	24.1 (8.96)	252	18.5 (10.17)	−0.46 (−2.16 to 1.26); P = 0.602	226	15.1 (10.84)	−1.63 (−3.48 to 0.21); P = 0.082
Control	227	22.4 (9.52)	195	16.9 (10.30)	REF	184	14.7 (10.65)	REF
Social functioning (WSAS score)
Intervention	302	17.3 (9.94)	237	14.7 (9.54)	0.48 (−1.03 to 2.00); P = 0.531	212	11.6 (9.59)	1.34 (−3.20 to 0.53); P = 0.160
Control	227	16.6 (10.06)	195	13.2 (9.90)	REF	183	12.0 (9.99)	REF
Quality of Life (EQ-5D-5L score)
Intervention	302	0.659 (0.232)	256	0.694 (0.236)	−0.002 (−0.0412 to 0.0372) P = 0.94	221	0.718 (0.249)	0.053 (0.013 to 0.093); P = 0.01
Control	226	0.667 (0.226)	197	0.708 (0.213)	REF	183	0.696 (0.225)	REF
Satisfaction with care (MISS total score)
Intervention	302	N/A		N/A		217	121.8 (27.37)	5.39 (−1.39 to 12.16); P = 0.119
Control	227	N/A		N/A		176	116.0 (26.75)	REF

^a Adjusted for baseline value, baseline anxiety (GAD-7 score), sociodemographics, past history of depression, and practice as a random effect. BDI-II = Beck Depression Inventory, Second Edition. GAD-7 = Generalised Anxiety Disorder questionnaire. MISS = Medical Interview Satisfaction Scale. REF = reference value. WSAS = Work and Social Adjustment Scale.

^b One patient withdrew immediately after enrolment and did not complete an EQ-5D-5L at baseline.